(1) Design conjugate peptide-based drugs or aggregation suppressors of higher efficacy and lesser side effects for the treatment of neurodegenerative diseases. 

(2) Explore the maximum application potential of novel nucleic acid analogs i.e. non-canonical nucleic acids or nucleic acids with modifications at different sites, majorly on base, sugar, and phosphate backbone.